Dr. Woyach on Ibrutinib Resistance in CLL

(1:47)

Dr. Woyach on the Safety of Acalabrutinib Versus Ibrutinib in CLL

(1:3)

Dr. Woyach on the Role of Acalabrutinib in CLL

(1:39)

Dr. Woyach on Treatment Challenges in CLL

(1:17)

Dr. Woyach Discusses Peripheral Lymphocytosis in Patients with CLL Taking Ibrutinib

(1:26)

Dr. Woyach on Ibrutinib and Peripheral Lymphocytosis in Patients with Chronic Lymphocytic Leukemia

(1:16)

Dr. Woyach on the Role of Chemoimmunotherapy in CLL

(1:25)

SDB Ethel Browne Harvey Postdoctoral Seminar Series - Yuchuan Miao and Kari Price

(57:35)

Cystoid Macular Edema

(1:52:35)

UofL Dept. of Medicine Research Grand Rounds: Dr. Leslie Wolf Parrish

(44:43)

Dr. Woyach on Remaining Sequencing Questions in CLL

(1:28)

Dr. Bhat on the Combination of Ibrutinib Plus FCR in Treatment-Naïve CLL

(1:47)

Comparison of BTK Inhibitors for CLL

(6:52)

Dr. Brown on Lessons Learned From RESONATE-2 Trial for CLL

(1:12)

Dr. John Byrd Summarizes the RESONATE Study Findings

(2:2)

Updates from the COSMOS trial: MOR208 for the treatment in R/R CLL

(2:19)

Ibrutinib significantly delays disease progression and extends survival in resistant or relapsed CLL

(5:4)

Dr. Woyach on the Role of Small Molecule Inhibitors in CLL

(1:8)

Dr. Woyach on Ibrutinib Regimens in Frontline CLL

(1:6)

Dr. Woyach Discusses Progression on Ibrutinib With the Acquisition of Resistance Mutations

(1:17)

Dr. Woyach Discusses Efficacy Findings from the RESONATE Trial

(40)

Dr. Woyach on Clinical Trials Examining Novel Triplets in CLL

(1:21)

Dr. Woyach on BTK Inhibition and the Mechanism of Action of Ibrutinib

(1:17)

Dr. Woyach Discusses the Efficacy Findings from the RESONATE Trial

(28)

Dr. Woyach on Using Ibrutinib in Combination Therapies

(1:53)

Dr. Woyach Discusses Progression on Ibrutinib With the Acquisition of Resistance Mutations

(1:31)

Dr. Woyach on 3-Year Follow-Up of Acalabrutinib/Obinutuzumab Combo in CLL

(1:20)

Dr. Woyach on the Results of the ELEVATE-TN Trial

(55)

Dr. Woyach on Preliminary Efficacy Results of MOR208 Trial in CLL

(49)